Tag Archives: disease

In May 2015, Global Genes launched their 2nd annual Cox Prize for Rare Compassion contest which encourages 1st and 2nd year medical students to get to know a rare family and write an essay based on their experiences. If the medical student does not have a rare family to work with, Global Genes will match them with a rare family in their local area.

In just a few weeks, they have had requests from over 90 medical students for help in being matched with a rare family! These students represent dozens of medical schools all over the U.S. as well as Canada and the U.K.

Global Genes is asking our help in finding rare families we can match for this program. This is a wonderful way to create awareness for your disorder within the medical education community and possibly create a relationship that could shape the med student’s future career focus. The IPPF would love to have pemphigus and pemphigoid families represented in this fantastic program! What a great way to help spread awareness to the future of the medical community about pemphigus and pemphigoid! To let Global Genes know that you are interested in being a rare family for this program please email Carrie Ostrea carrieo@globalgenes.org

Please help us spread the word about their med student matching program by going to http://globalgenes.org/cox-prize-family to see what locations are currently asking for requests. This list gets updated weekly, so please check back often to see what new cities are requested.

Thank you so much for your support! If you have any questions, please do not hesitate to ask.

Carrie Ostrea
Advocacy Director / Parent Advocate
Global Genes – Allies in Rare Disease
http://www.globalgenes.org
(949) 248-RARE x110

Having a flare after being in remission can be a scary and frustrating experience. Thoughts run through your head about your previous experiences and you may wonder if your disease will be as bad as it was before. When you have the flare, it is important to recognize it and take the challenge head-on. It’s easy to become stressed from the uncertainty and lack of control, but remember that stressing will only make things worse. Here are some tips to reduce the intensity and time that you may have the flare.

1.      Schedule an appointment with your doctor immediately.

2.      Have your doctor give you a clinical diagnosis or get a biopsy done to confirm the flare. There are many differential diagnoses for your disease so you want to be sure it is what you suspect.

3.      Discuss with your doctor a treatment strategy and begin right away.

4.      Track your disease activity in a log, this will help you determine if you condition is improving.

5.      Follow up with your doctor regularly and advocate for yourself. Seeing your doctor every 4-6 weeks is recommended. If you have an aggressive flare you may need to see your doctor more frequently.

6.      If you need support, contact the IPPF and talk with a Peer Health Coach. Coaches are available to answer questions and help you decide how to best handle your flare.

It is common for flares not to be as intense as your first experience with the disease, but all patients have different experiences. The important thing is to be proactive and stabilize the disease activity as soon as possible. Flares are part of living with pemphigus and pemphigoid but if they are handled quickly and with a positive attitude you can eliminate them sooner.

Remember, if you have questions to “Ask a Coach” because when you need us we are in your corner!

Please call Congress TODAY and ask them to include the OPEN ACT, HR 971 (Orphan Product Extensions Now, Accelerating Cures & Treatments) in the 21st Century Cures Legislation. The OPEN ACT has the potential to double the number of approved rare disease treatments available to patients. To date, 155 patient organizations support the OPEN ACT, including NORD, Global Genes, and the Genetic Alliance. By standing together we can ensure Congress helps rare disease patients.

Click here to take action: Stand up for Rare Disease Patients TODAY

Please share this alert widely and join this event on Facebook.

Why the OPEN ACT is important: Despite advances made possible by the Orphan Drug Act, 95 percent of the 7,000 rare diseases still have no approved treatments. Biopharmaceutical companies are not repurposing major market therapies to treat rare diseases because there is no incentive for them to do so.

The OPEN ACT is bipartisan legislation that creates an economic incentive for companies to repurpose drugs for rare diseases. The OPEN ACT could:
·         Bring hundreds of treatments to rare disease patients
·         Enable access to safe, effective and affordable treatments
·         Spur biotech investment, innovation, and foster clinical research at universities while creating new jobs

Learn more at: http://curetheprocess.org/ incentivize/

 

I recently spoke with a patient who stated that his marriage was under a great deal of strain – which is highly understandable as the significant others of patients are the caregivers and are often in the line of fire, so to speak.

This was not the first time a wife or husband had confided this to me. Helplessness can cause patients and/or their caregivers great despair – to which wanting to run away is an understandable reaction.

Patients experience pain, embarrassment, and uncertainty when afflicted with P/P or other rare diseases.

The caregivers can empathize, the caregivers cannot truly feel what the patients are experiencing.

Everyone who is a caregiver tries his or her best to be supportive. Every patient who is undergoing this challenge is bound to be depressed and scared at times. Every family member may feel helpless most of the time.

This is the time to reach out and ask for guidance. Finding support groups is easier these days due to social media. Pemphigus Vulgaris is only one of 7,000 rare diseases that exist today and there are sources of information for each one of them. Search the Internet and contact local support groups. Check out the link given here for caregivers (It’s one of the very best!).

http://www.caregiveraction.org/

Rare Disease Day (RDD) is a unique global advocacy effort to bring recognition of rare diseases as an international health challenge.

On March 2, 2015, rare disease patients, caregivers and advocates, rare disease organization, legislators, and industry representatives gathered at the California State Capitol. Will Zrnchik, IPPF CEO, welcomed the crowd and introduced Peter Saltonstall, President and CEO of the National Organization for Rare Disorders. Peter said, “NORD has been working … to find a therapy, make sure the pathways are clear, and to make sure that the incentives are there for industry to want to develop drugs for small populations.” California Assembly Member Katcho Achadjian (D-36) co-sponsored CA House Resolution 6 recognizing February 28, 2015 as Rare Disease Day in California.

_MG_9125                  _MG_9296

Inside the Capitol, Andrea Vergne, rare disease caregiver and advocate, told her grandson’s story living with a rare disease. Gary Sherwood, Communication Directors at the National Alopecia Areata Foundation, inspired attendees to become self-advocates and work with their elected officials. Adding to the advocacy theme, Eve Bukowski, California Healthcare Institute, echoed the need for patients to self-advocate. A special guest, California State Senator Dr. Richard Pan discussed the importance of rare disease advocacy and research.

Meanwhile, Marc Yale, IPPF Senior Peer Health Coach, and Kate Frantz, Awareness Program Manager, celebrated RDD events in Washington, DC. Marc attended NORD’s special preview of the new documentary “Banner on the Moon.” Patients, caregivers, advocacy groups and patient organizations saw Cindy Abbott’s inspiring. Cindy carries a NORD banner with her on several adventures to spread rare disease awareness. These included challenging herself to climb Mount Everest and participating in the 1,000-mile Alaskan Iditarod. Cindy’s perseverance and commitment to live life to the fullest were very inspiring.

Kate and Marc attended the American Medical Student Association’s Annual Convention. Two P/P patients, Liz Starrels and Mimi Levich, shared their P/P stories. Many students had never heard of P/P, or only briefly remembered it from their textbooks. This was a wonderful opportunity to spread awareness and encourage medical students to “Put P/P on their Radar!”

RDD 2                           RDD

Marc represented the P/P community at the Rare Disease Legislative Advocates (RDLA) conference.  There was an overview of the 21st Century Cures Initiative (http://energycommerce.house.gov/cures), which many believe is the rare disease community’s greatest hope for new and emerging treatments.

Marc also met with several Congressional Members and legislative health experts encouraging their support of the Orphan Product Extensions Now Accelerating Cures and Treatment Act of 2015, H.R. 971. This legislation would re-purpose existing drugs for rare diseases allowing patients greater access to vital treatments.

Marc RDD                                        Marc RDD 2

Marc attended a symposium celebrating rare diseases research efforts across NIH, the Federal Government and the entire advocacy community.

There are over 7,000 rare diseases. 1 in 10 Americans are affected and 95% of these diseases have no approved treatment. Rare Disease Week and Rare Disease Day is an opportunity for the Pemphigus and Pemphigoid community to be heard by advocating for yourself and others.

If you have questions about current legislation or would like information on how you can become involved, please contact marc@pemphigus.org.

This article was originally was posted at http://www.medscape.com/viewarticle/840206

The National Organization for Rare Disorders
The Importance of Rare Disease Education
Sophia A. Walker

February 25, 2015

Recently a wise professor told my class that we medical professionals are some of the most powerful people in the world. Indeed, we have the ability to meet people at their most vulnerable, sometimes on the very worst day of their lives, and help them. “This profession,” he told us, “is such a privilege that we must never miss the opportunity to have at least done some good for every patient.” Over the past several weeks, as I have planned rare disease awareness events and begun preparing to enter the clinical years of my medical education, I find myself considering these words more frequently. However, at the end of the day, I wonder how powerful we are, really…

My interest in rare diseases originated during my senior year of high school, when I first started volunteering at the National Organization for Rare Disorders, Inc. (NORD). I was overwhelmed to discover the many obstacles experienced by patients who have rare diseases. On a technical level, any disease that affects fewer than 200,000 Americans is considered rare. Of the more than 7000 rare diseases, only approximately 350 have treatments that are approved by the US Food and Drug Administration (FDA). I found that individuals with these diseases, almost two thirds of whom are children, show great courage and perseverance in the face of significant discouragement. Although I had always wanted to be a doctor, it was not until I witnessed such unrelenting determination to overcome barriers in healthcare that I discovered my own enthusiasm for medicine.

All physicians strive to provide attentive medical care with the utmost compassion and empathy; however, as medical professionals, we must also be our patients’ most vocal advocates. Although I was not yet a physician, I still wanted to contribute to this effort. I wanted to provide a forum for the nearly 30 million Americans with rare diseases whose voices often go unheard in the medical community, and I wanted to share this passion with my peers. Every year, my fellow students and I host a Rare Diseases Awareness Event. Patients, students, clinicians, and researchers come together to share their experiences and insights regarding rare diseases. We strive to shed light on the lives of these individuals by allowing them to share their own stories, sometimes for the very first time.

Although many students may assume that we do not need to know as much about rare diseases because we are unlikely to encounter them in our practice, this is simply not the case. In fact, every one of us preparing for medical careers will see patients with rare diseases, and the extent to which we prepare ourselves for this reality will determine the impact we can have on these patients’ lives. Patients who have a rare disease face difficulty in every step of medical care, including diagnosis, treatment, and preserving quality of life. Sometimes, patients go years without receiving the correct diagnosis for their condition. Once they finally have an answer, often no treatment is available for their condition. As future physicians, we must aim to improve these prospects; the first step in doing so involves developing a keen understanding of this patient population.

The opportunities for medical students to learn about rare diseases are vast. Gaining a basic understanding of how the experience of having a rare disease is different from having a more common disease is equally essential. The National Institutes of Health (NIH) has great information related to rare diseases on its website, and the NORD website provides overviews and links to more than 200 patient organizations that provide excellent information about specific rare diseases. Students can also apply for a free NORD student membership by writing to bhollister@rarediseases.org. Once you register, you receive a monthly eNews and quarterly newsletter specifically designed for students planning healthcare careers. If you’re attending the American Medical Student Association annual convention in Washington, DC, on February 27 and 28, come to the NORD booth in the exhibit hall where patients with rare diseases will be sharing their stories.

With each speaker I listen to at a rare diseases event, with each new person I meet, I am filled once again with immense pride that our efforts, if even in a small way, have done some good. Unlike many people who are involved in advocacy efforts in this area, when I began this work, I did not have a personal connection to rare diseases. However, after years of getting to know people who have experienced these struggles, I can say that I now have several. In fact, it is the memory of the individuals I have met and the satisfaction in having contributed to raising awareness that has guided my interests, served as an influence in many decisions, and ultimately has been the driving motivation in achieving my aspirations. With every step I take moving forward in my career, rare diseases comes along with me and will continue to do so.

My passion for rare diseases advocacy has become perhaps the foremost aspect that defines me and has made me who I am. It has given me direction, has made me a leader, and continually prepares me to become one of those physicians who will do some good. A couple of years ago, one of my undergraduate professors asked me, “Are you that rare diseases girl?” He went on to say that a student who had been inspired to research rare diseases after attending my event had approached him with an interest in working in his lab. This is the reason why I raise awareness for rare diseases. If just one more person every year becomes inspired, that may eventually make all the difference in the world. It turns out that, in the end, we are all powerful together. After all, according to the NORD motto: “Alone we are rare. Together we are strong.”®

A few weeks ago, I had the opportunity to interview Dr. Anne Pariser (US FDA Office of New Drugs, Rare Disease Program) and Dr. Gayatri Rao (US FDA Office of Orphan Products Development). We talked about the role of their departments, orphan drug development, repurposing drugs, and what the IPPF and our members can do to help.

BADRI RENGARAJAN: You work in the FDA’s Office of Orphan Products Development. What is the Office’s mandate, and what is its relationship with the rest of the FDA?

FDA: The Office was created over 30 years ago. At that time, there was very little focus on developing products for rare diseases. The primary mission of the Office is to promote the development of products for rare diseases. Prior to the passage of the Orphan Drug Act, companies did not have enough incentives to develop products for the rare disease space. The Orphan Drug Act was created to provide those incentives, including a designation and grants program. Our office administers these programs. We are not in the review divisions of the FDA that review marketing applications [i.e., applications that seek approval to market a drug], however, we work closely with them.
FDA: We deal with companies early on. We review products for purposes of orphan designation. There is a corollary designation program for devices. We also have two grants programs to stimulate research for rare diseases and pediatrics – the Orphan Products Grants Program and the Pediatric Devices Consortia Grants Program. Rare diseases have become a focus internally and externally, so, in addition to administering the designations and grants programs, we also serve as a cross-cutting function among all different parts of Agency. We encourage collaboration.

FDA: In addition, we are often the first stop for patients with rare diseases.

BR: It seems to be common wisdom that pharmaceutical companies do not develop drugs for orphan or rare diseases because the revenue opportunity is not attractive (due to small market)? Is the common wisdom correct? Why or why not?
FDA: This wisdom has evolved over time. When the Orphan Drug Act was initially passed, this was the case. Even after the Act was initially passed, we did not see a whole lot of designations come through. But this has changed over time.

Trial costs are rising, and exclusivity has been a good incentive. These days companies will generally see a return on their investment. The rare disease area is becoming a more attractive space – not just for small biotechnology companies but also for large pharmaceutical companies.
BR: How has the FDA made it easier or more attractive for drug companies to develop products in orphan/rare diseases?

FDA: With orphan designation, a company gets tax credits for clinical trial costs (up to 50%). If your product is the first to be approved for a particular rare disease indication [i.e., authorized use], you get 7 years of marketing exclusivity.

rphan designation also gets you a waiver of the FDA’s user fee ($1.9M), which is a fee companies who submit a marketing application to FDA must typically pay.

BR: How are the approval requirements for orphan drugs different?
FDA: To be approved in the U.S., all drugs must demonstrate substantial evidence of efficacy and safety, which is usually done through the conduct of at least one adequate and well-controlled clinical trial. There is no requirement that all drugs go through Phase 1, Phase 2, and two Phase 3 trials. This is often the case for common diseases, but each development program is different, and there has been considerable flexibility shown for rare disease development programs. The FDA can exercise flexibility and scientific judgment. It is important to work closely with FDA to discuss the design of clinical development programs for rare diseases that are able to demonstrate substantial evidence of efficacy and safety.

FDA: Most (about two-thirds) orphan drugs are approved based on one adequate and well-controlled clinical trial and supportive information. What constitutes substantial evidence of effectiveness and safety will depend on what is known about the disease and population studied, the drug, and several other factors.
BR: Are there even less strict requirements for drugs aimed at ultra-orphan diseases?

FDA: There is no official term of “ultra-orphan” diseases. All are rare (also known as orphan) diseases. In the U.S., an orphan disease is defined by law as one that has a prevalence of less than 200,000 in the U.S. Most rare diseases are low prevalence (10,000-20,000 patients or fewer). Most approved products are for low prevalence diseases.

BR: Are requirements for orphan/rare drugs the same in other countries? (for instance, Europe and Japan) If not, what are the key differences?
FDA: This is outside of our authority. The regulatory requirements are not completely harmonized. Most of the time, FDA and other International Conference on Harmonisation (ICH) regulatory agencies, such as the European Medicines Agency (EMA), agree on approval decisions for orphan drug applications, and orphan designations. Many programs are multinational and we do collaborate quite a bit with authorities in other countries.

BR: From a regulatory perspective, are all orphan/rare diseases the same? If not, what are the different categories?

FDA: There are 7,000 rare diseases. They affect different age groups, have widely varying symptoms, exhibit different disease severities, etc. We talk about rare diseases like they are monolithic, but they are highly diverse. When thinking about orphan designation, understanding the disease is very important (e.g., is it one single disease or two diseases?) We even give orphan designation for subsets of common diseases.
FDA: With rare diseases, there is limited opportunity for study so you have to understand what is feasible, but other factors about the disease, the drug, and the expected effects of intervention are very important. The general principles of clinical research still apply.
FDA: Product candidates that come to the FDA for review are routed by disease or therapeutic area to the review divisions. For instance, a drug for skin diseases would generally be reviewed by the Division of Dermatology and Dental Products (DDDP).

BR: Are pemphigus and pemphigoid different from other orphan diseases from a regulatory perspective?
FDA: We searched our orphan designation database. We haven’t seen a lot of orphan designations for pemphigus. Ultimately, the same fundamental regulatory, scientific and clinical research principles would apply to drug development for pemphigus as for other diseases; however, the specific considerations for clinical development of a drug for pemphigus should be discussed with the review division.
BR: For ultra-orphan diseases like pemphigus and pemphigoid, what happens if there just are not enough patients to enroll in a trial? For instance, people may be too frail to participate in the trial, or they may not live close enough to a clinical trial site such as an academic medical center.

FDA: Most of these diseases are low prevalence. Most rare diseases are serious disorders, and many have patients who are very ill and medically vulnerable. This is where the concept of flexibility comes in. There is considerable diversity in approaches to developing drugs for rare diseases. For instance, in two-thirds of situations, only one adequate and well-controlled (A & WC) trial or another non-traditional study design is done. In contrast, for most common diseases, two A&WC trials are usually done. In unusual cases for some diseases, a case series is submitted. There is an example of a drug development program in which a clinical study of 8 people supported the approval of a drug. The important thing is to collaborate and talk to the FDA early and to arrive at a good trial design. Through this, we can often be quite successful.

BR: The FDA approves drugs for particular uses or “indications.” However, physicians can prescribe drugs for non-approved uses. For instance, Rituximab is approved for several uses (e.g., rheumatoid arthritis, certain types of lymphoma) but not for pemphigus, yet some doctors use it to treat pemphigus. How is this possible?

FDA: Drugs are prescribed by practitioners off label all the time. Medication choice is governed by the practice of medicine. The FDA does not regulate clinical practice. Based on what a physician knows about a patient, he or she does what is in the best interests of that patient.

FDA: Whether a drug is on-label or off-label does have implications for reimbursement.

BR: If Rituximab™ were studied in a pemphigus trial, would it have a faster path for being approved for use in pemphigus?

FDA: It’s a complicated question. You are re-purposing the drug. If you have a new drug with no prior use in humans, you have a long path with toxicology and other preclinical work that needs to be done. With a repurposed drug, you may already have that early work completed. You may then be able to jump in right at phase 2 and phase 3, but it depends on the circumstance. One should contact the relevant FDA review division to discuss trial design. If Rituximab were studied in pemphigus or pemphigoid, it may be eligible for orphan drug designation and all the incentives, including exclusivity.

BR: Given off-label usage is possible, what would be the utility of conducting a trial of an already approved drug in a new disease indication like pemphigus?
FDA: If you are deliberately measuring outcomes in a group of people (versus simply prescribing the drug to single patients), it becomes more of a research situation and you need to consider conducting this under an investigational new drug application, which is a type of authorization for doing investigational work.
BR: What can patient organizations do to support and accelerate the development of drugs?
FDA: You can do a lot. For rare diseases, one of the biggest problems is that patients are sparsely dispersed. It can be difficult to enroll trials. Describing natural history is very important, and patient organizations can help here. Also, many physicians may not be trained to treat patients with this disease. Patient groups can start registries (with type of disease, geographic location, etc.). Some organizations have initiated treatment centers – so if a treatment becomes available, they would have expertise and best practices located at one site.

 

BR: Is there a particular stage of the drug development and regulatory process where patient organizations can be most impactful?

FDA: All phases. Early on, trying to establish research registries, centers of excellence, and clinical endpoints is helpful. With slow trial enrollment, patient organizations can turn around the situation. Patient groups can help all the way through.
BR: Is there anything a patient advocacy group can do to assist the FDA’s review and approval process?
FDA: The FDA has a patient representative program. Through this program, patients can provide perspective at FDA advisory meetings. It is also important to partner with sponsors [e.g., drug manufacturers]. Sponsors may be willing to share information from trials, whereas the FDA cannot provide such data.

BR: Are there particular orphan drug policy efforts at play in Washington, DC that we should be aware of?
FDA: It is hard for us to comment on legislative activities.

BR: Are there particular orphan/rare disease organizations or groups we should collaborate with?

FDA: More experienced and larger groups are always willing to mentor smaller groups (e.g., cystic fibrosis group will talk to you and give you advice). NORD and the Genetic Alliance also do a lot of mentoring. The Genetic Alliance has boot camps. Get in touch with the Office of Rare Diseases Research at NIH. They can be very helpful. Rare Disease Day seminars, web casts, and events can also be helpful.

Anti-p200 pemphigoid is a rare subepidermal blistering disease associated with autoantibodies against a 200kDa protein, reportedly corresponding to laminin γ1. However, direct evidence of the pathogenic potential of these antibodies is missing. We have followed up a patient with anti-p200 pemphigoid for five years. During this period she experienced a total of three generalised relapses. Quantifying our patient’s autoantibody concentrations against laminin γ1 by ELISA throughout the course of her disease we demonstrated a clear correlation with disease activity, thus providing first evidence of the possible pathogenic role of antibodies against laminin γ1 in anti-p200 pemphigoid. Further analysis by Western blotting revealed the occurrence of additional autoantibodies against α3 chain of laminin 332 1½ years after diagnosis, suggestive of intermolecular epitope spreading. Yet, the clinical appearance was unchanged and mucous membranes remained unaffected at any stage of the disease.

http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2133.2012.11076.x/abstract;jsessionid=2CC44AEBB9086AAB7009C30B7627506C.d02t01